GT Biopharma Granted 180-Day Extension by Nasdaq to Regain Minimum Bid Price Compliance

On May 20, 2026, GT Biopharma, Inc. received notification from the Nasdaq Listing Qualifications Staff granting the company an additional 180-day compliance period, extending until November 16, 2026, to regain compliance with Nasdaq’s Minimum Bid Price Requirement. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of at least $1.00 per share. The company was originally notified of its non-compliance on November 20, 2025, after its common stock failed to meet the minimum bid price for 30 consecutive business days. Nasdaq determined that GT Biopharma was eligible for the extension because it meets all other continued listing requirements for the Nasdaq Capital Market, including the market value of publicly held shares. To regain compliance, the company’s common stock must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the new deadline. The company is currently monitoring its stock price and evaluating options to satisfy the requirement.